Rosuvastatin (ZD 4522) is a competitiveHMG-CoAreductase inhibitor with anIC₅₀of 11 nM. Rosuvastatin potently blockshERGcurrent with anIC₅₀of 195 nM, delayed cardiac repolarization, and thereby prolonged action potential durations (APDs) and corrected QT interval (QTc) intervals. Rosuvastatin reduces the expression of the mature hERG and the interaction ofheat shock protein70 (Hsp70) with the hERG protein. Rosuvastatin effectively lowers low-density lipoprotein (LDL)cholesterol, triglycerides, and C-reactive protein levels^[1][2][3].

IC50: 11 nM (HMG-CoA), 195 nM (hERG)^[1][2]

Rosuvastatin (10 mg/kg, intraperitoneal) prolonges QTc in conscious and unrestraines guinea pigs from 201±1 to 210±2 ms^[2].
Rosuvastatin (20 mg/kg/day, for 2 weeks) significantly reduces very low-density lipoproteins (VLDL) in diabetes mellitus rats induced by Streptozocin^[4].

481.54

C₂₂H₂₈FN₃O₆S

287714-41-4

瑞舒伐他汀；罗苏伐他汀；罗素他汀；罗伐他汀

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.